BioGaia research wins first prize at LAB Symposium
The prestigious International Symposium on Lactic Acid Bacteria was held between 23–25 August and gathered more than 300 participants. Together with researchers from the Swedish University of Agricultural Sciences (SLU), BioGaia presented one of the more than 170 scientific posters at the symposium. This collaborative project was awarded first prize for “Outstanding Excellence in Lactic Acid Bacteria with an Industrial Relevance.” The award was presented by the Lactic Acid Bacteria Industrial Platform (LABIP).
LAB symposia are held every third year and characterised by the interplay between research and industry. While most content is pre-clinical, clinical trials are also presented. This year, the symposium was held online with more than 300 participants and over 170 scientific posters presented.
“We are very honoured to receive this award, especially when the theme of the symposium is exactly what BioGaia stands for – high-quality research into lactic acid bacteria with relevance for industrial applications and, ultimately, for consumers. The award is appreciated recognition by the research community that BioGaia and its partners are carrying out really high-quality research,” says Stefan Roos, associate professor at SLU and head of research into new bacteria strains at BioGaia.
In addition to the honour, prize money of EUR 500 was shared by Ludwig Lundberg and Yanhong Pang as first authors of the poster “Multifunctional membrane vesicles produced by L. reuteri DSM 17938 and their potential link to relief of infantile colic.” Ludwig Lundberg is an industrial PhD student at BioGaia and SLU, and a good example of how BioGaia partners with academic researchers.
The full list of poster authors:
Ludwig Lundberg*, Yanhong Pang*, Manuel Forsberg, Eva Sverremark Ekström, Gianfranco Grompone, Helena Bysell and Stefan Roos.
For further information, please contact:
Ulrika Engellau, PR & Corporate Communications Manager
Phone: +46 (0)72 235 15 00
Email: ule@biogaia.se
BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. To date, over 200 articles on clinical trials with BioGaia's probiotic strains have been published. The products are sold by nutrition and pharmaceutical companies in more than 100 countries. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com
Tags: